- Home
- Providers
- Rheumatology
- Rheumatoid Arthritis
查找地点
有关时间、上门服务和预约Rheumatoid arthritis affects an estimated 1.5 million people in the United States.1 For most people with RA, early diagnosis and treatment can control joint pain and swelling and lessen joint damage.
Labcorp is your trusted single-source solution for RA testing, from RA diagnosis to disease activity monitoring and treatment management.
Early RA diagnosis and initiation of disease-suppressing therapy may improve clinical outcomes and reduce the accrual of joint damage and disability.2 Labcorp offers several RA-specific markers that, when used in combination, provide industry-leading sensitivity and help support an early diagnosis of RA. Prognosis is dependent on early, accurate diagnosis and establishing an effective treatment plan.3 Diagnosis and classification of RA has relied heavily on anti-cyclic citrullinated peptide (Anti-CCP) and rheumatoid factor (RF) IgM.2 New markers are available to better identify patients with RA, stratify patients for risk of joint destruction and/or radiographic progression, and monitor disease activity and effectiveness of treatment.
RA Diagnosis
Labcorp’s RheumAssure panel contains Rheumatoid Factor (RF), Cyclic Citrullinated Peptide (CCP) Antibodies, and 14-3-3 eta protein tests.
RA Diagnosis
The RAdx6 combines four novel markers (14-3-3 eta, Anti-Sa, Anti-CEP-1, and Anti-CarP) with two traditional markers (Anti-CCP and RF-IgM) to enhance diagnosis in early or established RA and help predict disease severity.
RA Diagnosis
These diagnostic and prognostic panels are designed to complement traditional RF and Anti-CCP testing. The profile consists of 14-3-3 eta, Anti-Sa, Anti-CEP-1, and Anti-CarP.
SeroNeg RAdx4 Profile
RA Profile reflex to SeroNeg RAdx4
Achieving a state of disease remission in rheumatoid arthritis (RA) is a primary treatment goal. Until the desired treatment target is reached, drug therapy should be adjusted at least every three to six months. The desired treatment target should be maintained throughout the remaining course of the disease. Vectra provides an objective measure of RA inflammation and can be used to complement other disease activity measures.
RA Monitor & Prognosis
Vectra is an advanced blood test that objectively measures inflammation caused by rheumatoid arthritis.
Vectra provides a personalized score by measuring 12 biomarkers and incorporates information on age, gender and adiposity to measure RA inflammation and predict future risk of radiographic progression.5
RA Monitor & Prognosis
Vectra Cardiovascular Risk provides a personalized assessment of inflammation to predict an RA patient’s risk of a cardiovascular event in the next 3-years.6
Vectra is intended to be used at therapy initiation, change in drug therapy, and to monitor a patient once they achieve low disease activity
Although RA treatment is multifaceted, medications play an important role in patient management. Newly developed laboratory assays aid physicians in monitoring use and maximizing effectiveness of both disease-modifying anti-rheumatic drugs (DMARDs) and biologics.
RA Treatment Monitoring
Methotrexate (MTX) is subject to wide pharmacokinetic variability. About 30% of patients do not respond to MTX treatment or experience adverse effects.7 Testing for MTX PGs can help assess patient compliance and determine correct dosing to achieve therapeutic levels and clinical response.8
RA Treatment Monitoring
Hydroxychloroquine (HCQ) concentrations may be useful in achieving maximal clinical benefit while minimizing long-term retinal toxicity in lupus and other chronic autoimmune diseases. Monitoring HCQ may also improve adherence.
RA Treatment Monitoring
Thiopurine-related testing may be used to assess dosing before and during treatment, as well as to identify patients who may be at risk for drug toxicity.9 The FDA-approved label recommends testing consideration for the most common TPMT gene mutations (genotype) or TPMT activity (phenotype) before beginning treatment due to potentially severe bone marrow toxicity.
TPMT Genotyping
TPMT Enzyme Activity
Labcorp offers serum measurement of drug and anti-drug antibodies for patients on biologic drug therapy. Drug and anti-drug antibody levels provide the pharmacokinetic and immunogenic assessment that discerns the underlying mechanism of an inadequate response to biologic drug. Testing may be ordered at any time during therapy, though sample collection before the next infusion or injection is recommended.
Monitoring Biologics
Labcorp’s DoseASSURE™ suite of tests includes the following drugs and anti-drug antibodies:
Adalimumab and Anti-Adalimumab Antibody ADL
Certolizumab and Anti-Certolizumab Antibody CTZ
Etanercept and Anti-Etanercept Antibody ETN
Golimumab and Anti-Golimumab Antibody GOL
Infliximab and Anti-Infliximab Antibody IFX
Rituximab and Anti-Rituximab Antibody RTX
Ustekinumab and Anti-Ustekinumab Antibody UST
Rheumatology Services Hotline: 800-338-1918
Vectra® Customer Service: 877-743-8639
* Proposed algorithm for RA patients. A consensus has yet to be reached about target ranges and maximally effective concentrations.3 Optimal drug concentration is patient-specific and depends on disease and desired therapeutic endpoint.